This innovative FTSE 250 stock has had a solid start to the year, rising 15% in just two days. Is it time I considered adding ...

President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland ...

Canadian public and private insurers have balked at covering certain medication for weight-loss, but that might change as the ...

Access to Greenland’s minerals would give Washington more supply chain security and limit any leverage that China could to ...

The proportion of obese Indians has risen from 25 per cent in 2013 to 40 per cent in 2023, highlighting the need for ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Metsera (MTSR), which is developing ultra-long-acting drugs for obesity, has filed for a $100M initial public offering. Read more here.

A dozen GLP-1 receptor agonists and coagonists demonstrated effectiveness for weight loss in adults with obesity and without ...

Investors have shunned high-yielding stocks as long-term bond rates rise. But some dividend stocks, particularly energy and ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

Eli Lilly & Co. (LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026. CEO Dave Ricks ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...